Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.

Abstract

Novel targeted cancer therapies, especially kinase inhibitors, have revolutionized the treatment of many cancers and have dramatically improved the survival of several types of malignancies. Because kinases not only are important in cancer development and progression, but also play a critical role in the cardiovascular (CV) system and metabolic homeostasis, important CV and metabolic sequelae have been associated with several types of kinase inhibitors. This paper reviews the incidences and highlights potential mechanisms of vascular and metabolic perturbations associated with 3 classes of commonly used kinase inhibitors that target the vascular endothelial growth factor signaling pathway, the ABL kinase, and the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathway. We propose preventive, screening, monitoring, and management strategies for CV care of patients treated with these novel agents.

• Authors: Weijuan Li, Kevin Croce, David P Steensma, David F McDermott, Ori Ben-Yehuda, Javid Moslehi
• Journal: Journal of the American College of Cardiology (J Am Coll Cardiol) Vol. 66 Issue 10 Pg. 1160-78 (Sep 08 2015) ISSN: 1558-3597 [Electronic] United States
• PMID: 26337996 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Chemical References

• Protein Kinase Inhibitors

Topics

• Animals
• Cardiovascular System (drug effects)
• Disease Models, Animal
• Female
• Humans
• Male
• Molecular Targeted Therapy (methods)
• Neoplasms (drug therapy, mortality, pathology)
• Prognosis
• Protein Kinase Inhibitors (administration & dosage, adverse effects)
• Randomized Controlled Trials as Topic
• Risk Assessment
• Survival Analysis
• Treatment Outcome